Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine
| Autor: | Yaki Saciuk, Anat Ekka Zohar, Naama Shamir Stein, Jennifer Kertes |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty 2019-20 coronavirus outbreak COVID-19 Vaccines Adolescent Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Vaccine Efficacy Polymerase Chain Reaction mRNA BNT162b2 Internal medicine medicine Humans Immunology and Allergy Child BNT162 Vaccine Aged Retrospective Studies Vaccines Synthetic vaccine effectiveness SARS-CoV-2 business.industry Brief Report Infant Newborn COVID-19 Infant Retrospective cohort study Pfizer-BioNTech vaccine Middle Aged AcademicSubjects/MED00290 Infectious Diseases Child Preschool Health maintenance Female mRNA Vaccines business |
| Zdroj: | The Journal of Infectious Diseases |
| ISSN: | 1537-6613 0022-1899 |
| Popis: | A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of nearly 1 million members receiving 2 doses of BNT162b2 in January–February 2021, infection rates (based on polymerase chain reaction results) were compared between those who received a third dose with those who did not during August–October 2021 (maximum, 70 days). Crude VE was 92.9% (95% confidence interval [CI], 92.6%–93.2%) and adjusted VE was 89.1% (95% CI, 87.5%–90.5%). We conclude that the third dose provides added protection against SARS-CoV-2 infection for those vaccinated 6 months ago. Providing a third dose of BNT152b2 6 months after the first 2 doses evidenced a vaccine effectiveness against infection rate of 89%. The reduction in infection risk 2 months after the third-dose vaccination campaign reinforces the wisdom of its implementation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|